XML 44 R23.htm IDEA: XBRL DOCUMENT v3.19.2

Subsequent Events	6 Months Ended
	Jun. 30, 2019
Text block [abstract]
Subsequent Events	Note 17: Subsequent events On August 7, 2019, the Company announced the submission of its BLA to the FDA for Viaskin® Peanut for the treatment of peanut-allergic children ages 4 to 11 years. The Company evaluated subsequent events that occurred after June 30, 2019 through the date of approval of the unaudited condensed consolidated financial statements by the Board of Directors and determined that there are no other significant events that require adjustments or disclosure in such unaudited condensed consolidated financial statements.

X

- Definition

Text block [abstract]

+ References

No definition available.

+ Details

Name:	dbvt_TextBlockAbstract
Namespace Prefix:	dbvt_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 10
-IssueDate 2018-01-01
-Paragraph 21
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=10&date=2018-03-01&anchor=para_21&doctype=Standard
-URIDate 2018-03-16

+ Details

Name:	ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration